Phone: 800-926-4797 or 941-312-0400
Your membership provides this website - Join Today!

 

Updates on PWSA (USA) Research  

by Janalee Heinemann, PWSA (USA) Director of Research & Medical Affairs 

  • PWSA (USA) Research and Medical Affairs Director Janalee Heinemann and Director of Family Support Barb McManus maintain the medical database. The first health questionnaire (see www.pwsausa.org/population) received over 1,600 responses and the second is about to go out.  This journal article from France is an example of several published outcomes from this database.

    1) Journal of Intellectual Disability Research

    "Cross-cultural comparisons of obesity and growth in Prader-Willi syndrome," by O. Dudley1, B. McManus2, A. Vogels3, J. Whittington4, F. Muscatelli5 (2008)

    doi:10.1111/j.1365-2788.2008.01044.x

    1 Institute of Developmental Biology, Marseille - Luminy (IBDML), UMRCNRS 6156, Campus de Luminy, Marseille, France

    2 PWSA USA, Sarasota, FL, USA

    3 Department of Clinical Genetics, University Hospital of Leuven, Herestraat 49, B-3000, Leuven, Belgium

    4 Department of Developmental Psychiatry, 18b Trumpington Road, University of Cambridge, Cambridge, CB2 8AH, UK

    5 Mediterranean Institute of Neurobiology (INMED), Inserm U901, BP13, 13273, Marseille, France

    Lead author: Oenone Dudley, Institut de Biologie du Développement de Marseille-Luminy (IBDML), UMRCNRS 6156, Campus de Luminy, Case 907, 13288 Marseille, Cedex 9, France (e-mail: odudley@orange.fr).


    RESULTS
    : A total of 82.5% French adults with PWS have BMI > 30 compared with 65.8% in Belgium (n.s.), 58.2% in the USA (P < 0.005), and 54.3% in the UK (P < 0.01). Higher rates of obesity in females vs. males were found in the USA sample (P < 0.001) but not in the other samples. In contrast to adults, growth curves for French children with PWS show similar rates of growth compared with children with PWS in Germany and the USA. The principal determining factors of BMI status in the French PWS population are age (P < 0.0001), cohort (born within the last 15 years vs. born over 15 years ago, P < 0.0002) and growth hormone replacement therapy (P < 0.0002). Significant subsidiary effects include domestic situation (P < 0.0001), genetic diagnosis (P < 0.0001) and age of diagnosis (P < 0.0001).

    CONCLUSIONS: French adults with PWS have significantly higher rates of obesity than adults in the UK and the USA, but growth in French children with PWS is similar to the USA and Germany. Clinical management has a greater impact on obesity outcome in PWS than cultural factors.

     

    2) Spine. 2008 Feb 15;33(4):394-401.

    "Complications of Scoliosis Surgery in Prader-Willi Syndrome," by Accadbled F, Odent T, Moine A, Chau E, Glorion C, Diene G, de Gauzy JS.

    From the *Department of Orthopedic Surgery, Hôpital des Enfants, Toulouse, France; ?Department of Endocrinology, Prader-Willi Syndrome Reference Center, Hôpital des Enfants, Toulouse, France; ?Department of Orthopedic Surgery, Hôpital Necker Enfants Malades, Paris, France; §Department of Pediatric Orthopedics, Hôpital Lenval, Nice, France.


    RESULTS
    : Mean age at scoliosis diagnosis was 6.2 years (range 0.5-13.5). Mean age at surgery was 12.3 years (range 5-15). Mean follow-up was 5.4 years (range 2-18). There were 9 major complications (4 severe kyphosis above fusion, 2 deep infections, 1 transient paraplegia, 1 pseudarthrosis, 1 delayed wound healing). The 4 kyphosis required reoperation, 3 of which were complicated with permanent spinal cord injury. Minor complications affected 6 patients.

    CONCLUSION: Scoliosis surgery is frequently necessary in PWS and is associated with high rate of complications. These are often related to specific features of this syndrome the surgeon should recognize and consider.

    PMID: 18277871 [PubMed - as supplied by publisher]

     

     
  • Sex Hormones/Sexuality - Dr's Varda Gross-Tsur and Harry Hirsch of Israel -- are doing a study on gonadal function in PWS and sexual behavior.  To date, they have obtained blood samples from 79 individuals (children & adults) with PWS, and are doing ultrasounds of the ovaries and uterus, etc.  They said it is already clear to them that our PWS population represents a wide spectrum of reproductive hormone function, and that sexuality is a very important issue.   What this means to us: We already know by the four documented cases world-wide of women with PWS giving birth to a child (Two normal & two with Angelman syndrome) that we can no longer say they are all sterile, but this will help us understand the ranges of reproductive hormones.  It will also define further (as we have written in the Management book) the sexual and relationship needs of those with PWS.  
  • Psychotropic Medications - Although there have been significant advances in - and application of -- psychotropic medication with PWS, reactions to these medications are dramatically variable.  Dr. Elisabeth Dykens, Elizabeth Roof and colleagues are working to shed new light on why there is such variability in the respond to psychotropic medications.  They predict that this may related to genes involved in drug metabolism.  An example is that they have found that poor metabolizers may have negative side effects if given too high a dose.  Their study identifies the CYP450 enzyme status in those with PWS.  What this means to us:  With this study, we should be able to identify more accurately what drugs work better - and as important -- in what dosage for PWS. 
  • Genetics: Dr. Merlin Butler: is working on the expression of four genes between chromosome 15 breakpoints BP1 & BP2 in PWS and the impact on cognition and behavior.  The preliminary analysis of their data indicate that there is more expression of each gene when two alleles are present, but there is a significant amount of variation in expression from individual to individual regardless of the copy number.  New technology has allowed for identification of different size deletions within the type I and type II deletion subgroups which may help explain further the differences in expression.  What this means to us:  It means that more sophisticated and accurate testing is becoming available.  This will help us to define the genetic reasons for the differences in behavior and cognition within PWS. 
  • PWSA (USA) Sponsored young researchers to attend the Conference on Clinical Research for Rare Diseases.  What this means to us:  There are over 7,000 rare diseases.  These meetings gave visibility and focus to OUR rare disease and promoted strongly that researchers collaborate with advocacy groups. 

edited: 08/19/2008

Return to Home page

PWSA(USA) Disclaimer 

Membership
Payments

PWSA (USA)
Privacy Policy

PWSA (USA) Link Policy

Email PWSA(USA)

 Email Webmaster